Leo's Dupixent rival hits all endpoints in pivotal program

Leo Pharma’s tralokinumab has hit all the primary and secondary endpoints in its three pivotal trials. The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year, but the lack of numbers shared publicly make it impossible to gauge whether tralokinumab is a threat to Sanofi and Regeneron’s blockbuster incumbent.